Ibrahimkhalil-Mohamud Ibrahim Sheikh

Dr. Ibrahimkhalil-Mohamud Ibrahim Sheikh


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2026 in Gastroenterology Insights
Verified
Journal Article
Open access
PDF file
SKSaksham Kohli
Saksham Kohli
APAnil Philip
Anil Philip
PSPhilip Sarpong-Mensah
Philip Sarpong-Mensah
YAYetunde Akande
Yetunde Akande
ISIbrahimkhalil-Mohamud Ibrahim Sheikh
Ibrahimkhalil-Mohamud Ibrahim Sheikh
HMHemant Mutneja
Hemant Mutneja
Background: Clostridioides difficile infection (CDI) remains a leading cause of hospital-acquired infection. Metabolic-dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and has been associated with increased infectious susceptibility. However, whether non-cirrhotic MASLD independently worsens inpatient CDI outcomes and whether this differs across the MASLD spectrum remain unclear. Methods: We conducted a retrospective cohort study using the National Inpatient Sample (NIS) 2017–2023, identifying adult hospitalizations with a principal diagnosis of CDI. Patients with cirrhosis and alcoholic liver disease were excluded. Propensity score matching (1:1) was performed for the primary MASLD vs. non-MASLD comparison in the principal-diagnosis CDI cohort. To evaluate whether outcomes differ across the MASLD spectrum, survey-weighted multivariable logistic regression was used to compare K76.0-coded (MASLD without steatohepatitis) and K75.81-coded (MASH) hospitalizations against non-MASLD/MASH hospitalizations within the principal-diagnosis CDI cohort. The primary outcome was in-hospital mortality; secondary outcomes included complications, healthcare utilization, and discharge disposition. Results: The principal-diagnosis CDI cohort comprised 76,103 discharges (weighted ~380,515). MASLD prevalence among non-cirrhotic CDI hospitalizations nearly doubled from 1.98% in 2017 to 3.74% in 2023 (OR per year 1.089; p < 0.001). After propensity score matching (1756 pairs), MASLD was not associated with significantly higher in-hospital mortality (OR 1.252; p = 0.574) or most adverse outcomes, but was associated with lower odds of non-routine discharge (OR 0.794; p = 0.003). In the matched utilization analysis, length of stay and total charges were not significantly different, although the adjusted pre-match analysis showed higher charges among MASLD hospitalizations (+$4431; p = 0.001). Within the same principal-diagnosis cohort, K76.0-coded MASLD (n = 1988) was associated with lower odds of acute kidney injury (aOR 0.821; p = 0.004) and non-routine discharge (aOR 0.805; p = 0.001). K75.81-coded MASH (n = 197) was independently associated with higher in-hospital mortality (aOR 2.840, 95% CI 1.154–6.985; p = 0.023) and peritonitis (aOR 4.136, 95% CI 1.543–11.082; p = 0.005), although confidence intervals were wide and the number of MASH-coded hospitalizations was modest. Conclusions: The prevalence of MASLD among CDI hospitalizations is rising. Non-cirrhotic MASLD without steatohepatitis does not independently worsen inpatient CDI outcomes after adjustment, whereas K75.81-coded MASH may identify a higher-risk subgroup with increased mortality and peritonitis, pending confirmation in larger cohorts. These findings suggest that hepatic inflammatory activity, rather than steatosis alone, may drive adverse CDI outcomes and support further investigation of MASLD phenotyping in CDI risk stratification.

Verified
Journal Article
Open access
PDF file
SKSaksham Kohli
Saksham Kohli
APAnil Philip
Anil Philip
YAYetunde Akande
Yetunde Akande
PSPhilip Sarpong-Mensah
Philip Sarpong-Mensah
ISIbrahimkhalil-Mohamud Ibrahim Sheikh
Ibrahimkhalil-Mohamud Ibrahim Sheikh
HMHemant Mutneja
Hemant Mutneja
Background: Alcoholic hepatitis (AH) is associated with high short-term morbidity and mortality, but contemporary national data on hospital readmissions remain limited. Methods: Using the Nationwide Readmissions Database (2016–2022), we identified adult non-elective AH index admissions and characterized readmission burden, predictors, and outcomes using survey-weighted Cox proportional hazards and Fine-Gray competing risks models. Results: Among 121,984 weighted AH index hospitalizations, 25.0% experienced a 30-day readmission. The most common readmission diagnoses were alcoholic cirrhosis with ascites (18.9%), recurrent alcoholic hepatitis with (12.5%) and without ascites (8.9%), sepsis (11.3%), and alcohol withdrawal (5.7%). Liver-related, other/systemic, and alcohol-related non-liver diagnoses accounted for 53.6%, 36.6%, and 9.8% of 30-day readmissions. Readmissions carried higher in-hospital mortality (8.6% vs. 3.3%; aOR 2.75), longer length of stay (7.1 vs. 6.4 days), higher mean charges ($77,606 vs. $60,491), and higher liver transplantation rates (all p < 0.001). Independent predictors of 30-day readmission included age (HR 0.9954 per additional year, p < 0.001), female sex (HR 1.13), discharge against medical advice (HR 1.89), higher comorbidity burden (Category 4 HR 1.30), diabetes (HR 1.13), chronic kidney disease (HR 1.13), acute kidney injury (HR 1.23), and blood transfusion (HR 1.23). Index ICU admission was paradoxically associated with lower readmission rates (OR 0.77) but higher mortality when readmitted (OR 2.38, p < 0.001). Conclusions: One in four AH survivors experienced a 30-day readmission, predominantly liver-related and carrying nearly threefold higher in-hospital mortality. Readmission risk was concentrated among patients with high comorbidity burden, identifying high-yield targets for early risk stratification and post-discharge intervention.